Stock Scorecard
Stock Summary for Unity Biotechnology Inc (UBX) - $1.19 as of 11/19/2024 2:59:14 PM EST
Total Score
12 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for UBX
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for UBX
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for UBX
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for UBX
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for UBX (17 out of 90)
Stock Price Rating (Max of 10) | 2 |
Historical Stock Price Rating (Max of 10) | 9 |
Stock Price Trend (Max of 10) | 1 |
Book Value (Max of 10) | 1 |
Book Value to Price (Max of 10) | 1 |
Analyst Buy Ratings (Max of 5) | 0 |
Analyst Strong Buy Ratings (Max of 5) | 0 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 3 |
Price to Earnings (Max of 10) | 0 |
Latest News for for UBX
Financial Details for UBX
Company Overview |
|
---|---|
Ticker | UBX |
Company Name | Unity Biotechnology Inc |
Country | USA |
Description | Unity Biotechnology, Inc., a biotechnology company, is dedicated to the research and development of therapies to slow, stop, or reverse the diseases of aging. The company is headquartered in South San Francisco, California. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 9/30/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 1.19 |
Price 4 Years Ago | 52.40 |
Last Day Price Updated | 11/19/2024 2:59:14 PM EST |
Last Day Volume | 58,862 |
Average Daily Volume | 65,743 |
52-Week High | 2.17 |
52-Week Low | 1.10 |
Last Price to 52 Week Low | 8.18% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 22.60 |
Sector PE | 40.32 |
5-Year Average PE | -1.36 |
Free Cash Flow Ratio | 0.69 |
Industry Free Cash Flow Ratio | 12.03 |
Sector Free Cash Flow Ratio | 27.97 |
Current Ratio Most Recent Quarter | 3.45 |
Total Cash Per Share | 1.72 |
Book Value Per Share Most Recent Quarter | 0.84 |
Price to Book Ratio | 1.44 |
Industry Price to Book Ratio | 5.31 |
Sector Price to Book Ratio | 20.88 |
Price to Sales Ratio Twelve Trailing Months | 6.54 |
Industry Price to Sales Ratio Twelve Trailing Months | 11.82 |
Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
Analyst Buy Ratings | N/A |
Analyst Strong Buy Ratings | N/A |
Share Statistics |
|
Total Shares Outstanding | 16,850,400 |
Market Capitalization | 20,051,976 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | 10.36% |
Reported EPS 12 Trailing Months | -1.28 |
Reported EPS Past Year | -1.03 |
Reported EPS Prior Year | -2.55 |
Net Income Twelve Trailing Months | -21,909,000 |
Net Income Past Year | -39,860,000 |
Net Income Prior Year | -44,469,000 |
Quarterly Revenue Growth YOY | -100.00% |
5-Year Revenue Growth | 0.00% |
Operating Margin Twelve Trailing Months | 0.00 |
Balance Sheet |
|
Total Cash Most Recent Quarter | 29,037,000 |
Total Cash Past Year | 43,201,000 |
Total Cash Prior Year | 94,795,000 |
Net Cash Position Most Recent Quarter | 29,037,000 |
Net Cash Position Past Year | 22,834,000 |
Long Term Debt Past Year | 20,367,000 |
Long Term Debt Prior Year | 20,367,000 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 0.58 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 28,398,000 |
Total Stockholder Equity Prior Year | 56,084,000 |
Total Stockholder Equity Most Recent Quarter | 14,144,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -22,547,000 |
Free Cash Flow Per Share Twelve Trailing Months | -1.34 |
Free Cash Flow Past Year | -37,111,000 |
Free Cash Flow Prior Year | -52,510,000 |
Options |
|
Put/Call Ratio | 0.11 |
Has Options | False |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.04 |
MACD Signal | -0.05 |
20-Day Bollinger Lower Band | 1.18 |
20-Day Bollinger Middle Band | 1.42 |
20-Day Bollinger Upper Band | 1.65 |
Beta | 0.83 |
RSI | 42.00 |
50-Day SMA | 3.92 |
150-Day SMA | 0.00 |
200-Day SMA | 13.56 |
System |
|
Modified | 11/19/2024 2:59:15 PM EST |